SAN DIEGO, Nov. 10, 2014 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that it will participate in two investor conferences in November.
-
On November 12th, TearLab will participate in the 2014 Stephens Fall Investment Conference at the New York Palace Hotel in New York City.
-
On November 20th, TearLab will present at the Canaccord Genuity Medical Technology & Diagnostics Forum at the Westin Grand Central Hotel in New York City. The presentation will begin at 2:30 PM Eastern Time. The presentation will be webcast live and archived for at least 90 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 17, 2014, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 6, 2014. We do not undertake to update any forward-looking statements.
CONTACT: Stephen Kilmer
(647) 872-4849
skilmer@tearlab.com
